{"analyses":[{"ciLowerLimit":"0.09","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.32","estimateComment":"A hazard ratio \\< 1 favours osimertinib","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","paramType":"Hazard Ratio (HR)","paramValue":"0.17","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"NA - Not calculated as insufficient number of events to enable the median and 95% confidence interval to be calculated","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"NA - Not calculated as insufficient number of events to enable the upper limit of the 95% confidence interval to be calculated","groupId":"OG001","lowerLimit":"7.36","upperLimit":"NA","value":"14.88"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"73"}],"units":"Participants"}],"description":"Time from randomisation until the date of CNS disease progression or death (by any cause in the absence of CNS progression) regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy prior to progression, based on CNS BICR assessment according to RECIST v1.1","dispersionType":"95% Confidence Interval","groups":[{"description":"80mg once daily tablet","id":"OG000","title":"Osimertinib"},{"description":"Matching Placebo","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"Full analysis set","reportingStatus":"POSTED","timeFrame":"Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months","title":"Central Nervous System (CNS) Progression-free Survival (PFS) by Blinded Independent Central Review (BICR)","type":"SECONDARY","unitOfMeasure":"Months"}